Rapt Therapeutics Inc at Wells Fargo Healthcare Conference Transcript
Great. Thanks, everyone, for joining us. Let's get started. We are very fortunate to have RAPT CEO, Brian Wong with us today for a fireside chat. Hi, Brian. Thank you for being here.
Thank you, [Ian]. Appreciate the opportunity.
Questions & Answers
Yes. So could you -- I think, for people who may not be familiar with -- to the RAPT story, could you give a brief overview about the company's platform and programs?
Sure, absolutely. So RAPT Therapeutics is focused on the discovery, development, and commercialization of oral small molecule that targets the immunological drivers of, both inflammation and cancer.
We have two lead programs. Our lead program in inflammation is called RPT193. This is currently in a Phase 2b trial in patients with moderate to severe atopic dermatitis. And we've demonstrated in our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |